FORTRAS: Phase I, Investigator Initiated, Dose-escalation Clinical Trial Evaluating a CD8 Alpha/Beta Armored RAS G12D/HLA-A*11:01-specific T-cell Receptor Therapy (MSK-TCR5) in Patients With Advanced Solid Tumors

Inclusion Criteria: Part A: Prior to cell collection all of the following inclusion criteria must be met: * Age ≥18 years. * Histologically confirmed advanced or metastatic, unresectable solid tumor * Positive for RAS G12D mutation and HLA-A\*11:01 allele * Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease after at least 1 line of systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options. Subjects with stable disease (SD), or that present lack of clinical benefit from previous therapy (inclu…